Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.11)
# 460
Out of 5,245 analysts
106
Total ratings
51.92%
Success rate
13.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $52 → $43 | $23.39 | +83.84% | 5 | May 8, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Neutral | n/a | $39.75 | - | 9 | Apr 2, 2026 | |
| SLDB Solid Biosciences | Initiates: Buy | $26 | $6.62 | +292.75% | 1 | Mar 20, 2026 | |
| MAZE Maze Therapeutics | Maintains: Buy | $46 → $58 | $25.78 | +124.98% | 4 | Mar 4, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $299.45 | -5.16% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $54.09 | +58.99% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $35.44 | +26.98% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $1.51 | +363.58% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $6.56 | +204.88% | 1 | Feb 11, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.25 | +84.62% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $39 | $29.68 | +31.40% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $19 | $16.80 | +13.10% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.11 | +487.08% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $24.19 | +292.72% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $75.56 | +21.76% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $5.23 | +91.39% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $12.60 | +11.11% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $434.52 | +25.66% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $17.37 | +187.85% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $28.64 | +92.04% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.97 | +506.06% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $11.27 | +50.84% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $50.36 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $7.23 | +162.79% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.80 | +478.95% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.00 | +1,350.00% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $297.45 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $5.49 | +410.02% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $6.38 | +213.48% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $25.61 | +110.86% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.44 | +4,066.67% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.14 | - | 3 | Jun 26, 2017 |
Ultragenyx Pharmaceutical
May 8, 2026
Maintains: Buy
Price Target: $52 → $43
Current: $23.39
Upside: +83.84%
Centessa Pharmaceuticals
Apr 2, 2026
Downgrades: Neutral
Price Target: n/a
Current: $39.75
Upside: -
Solid Biosciences
Mar 20, 2026
Initiates: Buy
Price Target: $26
Current: $6.62
Upside: +292.75%
Maze Therapeutics
Mar 4, 2026
Maintains: Buy
Price Target: $46 → $58
Current: $25.78
Upside: +124.98%
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $299.45
Upside: -5.16%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $54.09
Upside: +58.99%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $35.44
Upside: +26.98%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $1.51
Upside: +363.58%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $6.56
Upside: +204.88%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.25
Upside: +84.62%
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $29.68
Upside: +31.40%
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $16.80
Upside: +13.10%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $5.11
Upside: +487.08%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $24.19
Upside: +292.72%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $75.56
Upside: +21.76%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $5.23
Upside: +91.39%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $12.60
Upside: +11.11%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $434.52
Upside: +25.66%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $17.37
Upside: +187.85%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $28.64
Upside: +92.04%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $2.97
Upside: +506.06%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $11.27
Upside: +50.84%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $50.36
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $7.23
Upside: +162.79%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.80
Upside: +478.95%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.00
Upside: +1,350.00%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $297.45
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $5.49
Upside: +410.02%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $6.38
Upside: +213.48%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $25.61
Upside: +110.86%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.44
Upside: +4,066.67%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $28.14
Upside: -